Incyte, Eli Lilly Expand Collaboration | GenomeWeb

Incyte Genomics of Palo Alto, Calif., and Eli Lilly of Indianapolis have expanded an agreement to collaborate on accelerating the development of therapeutic proteins. Under the terms of the new agreement, Eli Lilly and Incyte will focus on identifying and selecting secreted molecules that are strong candidates for therapeutic protein development. Eli Lilly will also obtain options to license multiple therapeutic protein patents from Incyte.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.